A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis
- PMID: 38811470
- PMCID: PMC11169114
- DOI: 10.1007/s13555-024-01185-1
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis
Abstract
Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading to poor quality of life, especially in patients with moderate-to-severe disease. Since atopic and non-atopic comorbidities can further worsen the disease course, accurate establishment of the patient's individual intrinsic risk profile and needs is crucial and may help in guiding the selection of the best treatment option. Better quality of care for patients with AD can be delivered through a multidisciplinary team led by a dermatologist, for comprehensive patient management. The implementation of a multidisciplinary approach for AD could enhance the delivery of optimised and safe treatments, improve the standard of care and patient outcomes in the short and long term, and prevent or delay the lifelong impact of uncontrolled AD. Understanding the unmet needs, assessing correctly the patient risk profile and enhancing the shared patient-physician decision-making process can lead to disease control and quality-of-life improvement, especially in the context of the introduction of newer treatment for AD. This narrative review is a call for more data to establish standardised patient profiles and multidisciplinary strategies in AD management. In view on the fast-evolving treatments for AD, this review aims at highlighting the importance of a multidisciplinary approach to a comprehensive assessment and holistic care in patients with moderate-to-severe AD.
Keywords: Holistic care; Moderate-to-severe atopic dermatitis; Multidisciplinary approach.
© 2024. The Author(s).
Conflict of interest statement
Paolo Amerio: acted as investigator, consultant and speaker for AbbVie, Eli Lilly, Sanofi, Galderma, Pfizer, Novartis, Leo Pharma; Silvia Mariel Ferrucci: acted as a principal investigator in clinical trials for AbbVie, Galderma, Amgen, Sanofi, Eli Lilly, Almirall, Novartis, Bayer and as a speaker and advisor for AbbVie, Almirall, Leo Pharma, Pfizer, Novartis, Menarini, Sanofi, Lilly; Marco Galluzzo: acted as a speaker and/or consultant for AbbVie, Almirall, Eli-Lilly, Janssen-Cilag, LeoPharma, Novartis, Sanofi, and acted as a principal investigator in clinical trials for Almirall, Incyte Corporation, Janssen-Cilag, LeoPharma, outside the submitted work; Maddalena Napolitano: acted as speaker, consultant and/or advisory board member for AbbVie, Eli Lilly, Leo Pharma, Novartis, and Sanofi; Alessandra Narcisi: acted as investigator, consultant, speaker and/or advisory board member for AbbVie, Eli Lilly, Novartis, UCB, Almirall, Leo Pharma, Pfizer, Sanofi, Janssen; Cataldo Patruno: acted as investigator, speaker, consultant, and/or advisory board member for AbbVie, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi; Mariateresa Rossi: acted as investigator, speaker, consultant, and/or advisory board member for AbbVie, Sanofi, Eli Lilly, Galderma, Leo Pharma, Pfizer, L’Oréal Paris; Anna Levi, Sara Di Fino, Chiara Palladino: employees of AbbVie and may own AbbVie stocks/options.
Similar articles
-
Patients' and Caregivers' Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries.J Allergy Clin Immunol Pract. 2023 Jan;11(1):264-273.e1. doi: 10.1016/j.jaip.2022.10.032. Epub 2022 Nov 2. J Allergy Clin Immunol Pract. 2023. PMID: 36332836
-
Physician Perception of Disease Severity and Treatment Outcomes for Children and Adolescents with Atopic Dermatitis in Emerging Economies.Dermatol Ther (Heidelb). 2022 Apr;12(4):999-1013. doi: 10.1007/s13555-022-00708-y. Epub 2022 Mar 26. Dermatol Ther (Heidelb). 2022. PMID: 35349107 Free PMC article.
-
Review of the holistic management of pediatric atopic dermatitis.Eur J Pediatr. 2022 Apr;181(4):1363-1370. doi: 10.1007/s00431-021-04341-3. Epub 2022 Jan 22. Eur J Pediatr. 2022. PMID: 35064309 Review.
-
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. Am J Clin Dermatol. 2022. PMID: 35567671 Free PMC article. Clinical Trial.
-
Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review.Dermatol Ther (Heidelb). 2022 Dec;12(12):2653-2668. doi: 10.1007/s13555-022-00819-6. Epub 2022 Oct 5. Dermatol Ther (Heidelb). 2022. PMID: 36197589 Free PMC article. Review.
Cited by
-
Causal relationship and mediation effects of immune cells and plasma metabolites in atopic dermatitis: A Mendelian randomization study.Medicine (Baltimore). 2024 Oct 11;103(41):e39932. doi: 10.1097/MD.0000000000039932. Medicine (Baltimore). 2024. PMID: 39465865 Free PMC article.
-
Recent Advances in Inflammatory Skin Diseases: Future Research on Viral Reactivations and Vaccine Improvement.J Clin Med. 2024 Dec 2;13(23):7347. doi: 10.3390/jcm13237347. J Clin Med. 2024. PMID: 39685805 Free PMC article.
-
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel.Dermatol Ther (Heidelb). 2025 May;15(5):1063-1078. doi: 10.1007/s13555-025-01391-5. Epub 2025 Mar 31. Dermatol Ther (Heidelb). 2025. PMID: 40164817 Free PMC article. Review.
-
From Itch to Access: Psychodermatological Care Challenges and the Promise of Telehealth.J Clin Med. 2025 Mar 15;14(6):1993. doi: 10.3390/jcm14061993. J Clin Med. 2025. PMID: 40142801 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous